A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,101–2,200 of 3,966
A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis
Blackwell, T. S., Hewlett, J. C., Mason, W. R., Martin, S., Greco, J. D., Ding, G., Wu, P., LANCASTER, L. H., Loyd, J. E., Dudenhofer, R. B., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-108oc · Cited by 11
Self-citationEmerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1931119 · Cited by 12
Rethinking Idiopathic Pulmonary Fibrosis
Oldham, J. M., & Vancheri, C. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.005 · Cited by 13
Kim, J. S., Dashti, H. S., Huang, T., Cade, B. E., Podolanczuk, A. J., O’Hearn, D. J., Hoffman, E. A., Wang, H., Blaikley, J., Barr, R. G., et al. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13475 · Cited by 10
Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Kang, J., & Song, J. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-97396-z · Cited by 12
Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
Bourne, M. H., Kottom, T. J., Hebrink, D. M., Choudhury, M., Leof, E. B., & LIMPER, A. H. (2021) · Cells · doi:10.3390/cells10123502 · Cited by 10
Usual interstitial pneumonia: a clinically significant pattern, but not the final word
Larsen, B. T. (2022) · Modern Pathology · doi:10.1038/s41379-022-01054-2 · Cited by 10
Oruqaj, G., Karnati, S., Kotarkonda, L. K., Boateng, E., Bartkuhn, M., Zhang, W., Ruppert, C., Günther, A., Bartholin, L., Shi, W., et al. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.11.006 · Cited by 14
Sabater, L., Gossart, J. B., Hernandez, I., Rico, D., Blanchard, A. D., Borthwick, L. A., Fisher, A. J., Majo, J., Jiwa, K., Collins, A., et al. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.12.015 · Cited by 11
Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
Alhamad, E. (2015) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.146866 · Cited by 10
Bendstrup, E. M., Hyldgaard, C., Altraja, A., Sjåheim, T., Myllärniemi, M., Guðmundsson, G., Sköld, M. C., & Hilberg, O. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.28348 · Cited by 12
Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
Gupta, D., Dhooria, S., & Agarwal, R. (2015) · Lung India · doi:10.4103/0970-2113.148396 · Cited by 10
Confluent fibrosis and fibroblast foci in fibrotic non‐specific interstitial pneumonia
Churg, A., & Bilawich, A.-M. (2016) · Histopathology · doi:10.1111/his.12950 · Cited by 10
Idiopathic pulmonary fibrosis: an Australian perspective
Prasad, J. D., Holland, A. E., Glaspole, I., & Westall, G. P. (2016) · Internal Medicine Journal · doi:10.1111/imj.13078 · Cited by 13
Self-citationTargeting the myofibroblast to improve wound healing
Hinz, B. (2016) · Elsevier eBooks · doi:10.1016/b978-1-78242-455-0.00003-3 · Cited by 13
Hosein, K., Le, J., & Mura, M. (2016) · Lung · doi:10.1007/s00408-016-9963-3 · Cited by 12
Koegelenberg, C. F. N., Ainslie, G., Dheda, K. U. J., Allwood, B., Wong, M., Lalloo, U., Abdool-Gaffar, M. S., Khalfey, H., & Irusen, E. M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.05 · Cited by 10
Integrated Transitions of Care for Patients With Rare Pulmonary Diseases
Moreo, K., Lattimer, C., Lett, J. E., Heggen, C. L., & Simone, L. (2017) · Professional Case Management · doi:10.1097/ncm.0000000000000198 · Cited by 11
Mooney, J. J., & Collard, H. R. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.08.1172 · Cited by 10
Pirfenidone-induced phototoxic reaction in a patient with idiopathic pulmonary fibrosis
Woo, Y. J., Sohn, K. M., Kang, H., et al. (2017) · European Journal of Dermatology · doi:10.1684/ejd.2017.3079 · Cited by 10
Idiopathic pulmonary fibrosis: A guide for nurse practitioners
Vega‐Olivo, M., & Criner, G. J. (2018) · The Nurse Practitioner · doi:10.1097/01.npr.0000531121.07294.36 · Cited by 11
Tuyls, S., Verleden, S. E., Wuyts, W. A., Yserbyt, J., Vos, R., & Verleden, G. M. (2018) · Transplant International · doi:10.1111/tri.13382 · Cited by 10
Cassone, G., Sebastiani, M., Vacchi, C., Cerri, S., Salvarani, C., & Manfredi, A. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101051 · Cited by 16
Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis
Aussedat, P. H., Chebib, N., Ahmad, K., Glérant, J., Drevet, G., Grima, R., Maury, J., Nasser, M., Thivolet-Béjui, F., Traclet, J., et al. (2020) · Respiration · doi:10.1159/000509557 · Cited by 11
Mari, P., Wells, A. U., & Richeldi, L. (2019) · doi:10.1183/9781849840798.010518 · Cited by 11
Ambulatory and short-burst oxygen for interstitial lung disease
Sharp, C., Adamali, H. I., & Millar, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011716 · Cited by 10
Caveolin-1-Derived Peptide Reduces ER Stress and Enhances Gelatinolytic Activity in IPF Fibroblasts
Komatsu, S., Fan, L., Idell, S., Shetty, S., & Ikebe, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063316 · Cited by 10
Wu, X., Li, W., Luo, Z., & Chen, Y. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02861-w · Cited by 9
Lee, K., Lee, J. H., Koh, S. Y., Park, H., & Goo, J. M. (2025) · European Radiology · doi:10.1007/s00330-025-11714-x · Cited by 10
Wei, Y., Hou, J., Lü, P., Fu, L., Wang, X., Huang, Y. L., Chen, L., & Lv, C. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132012 · Cited by 9
Okuno, D., Sakamoto, N., Akiyama, Y., et al. (2022) · Cells · doi:10.3390/cells11182816 · Cited by 9
Dexmedetomidine alleviates pulmonary fibrosis through the ADORA2B-Mediated MAPK signaling pathway
Lai, X., Lin, Y., Huang, S., Pu, L., Zeng, Q., Wang, Z., & Huang, W. (2023) · Respiratory Research · doi:10.1186/s12931-023-02513-3 · Cited by 10
Murgo, A., Bignami, F., Federico, G., Villetti, G., Civelli, M., Sala, A., & Miglietta, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303646 · Cited by 13
Circular RNAs and their roles in idiopathic pulmonary fibrosis
Surendran, A. M., Huang, C., & Liu, L. (2024) · Respiratory Research · doi:10.1186/s12931-024-02716-2 · Cited by 14
Selvan, K. C., Reicher, J. J., Muelly, M. C., Kalra, A., & Adegunsoye, A. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03021-w · Cited by 11
Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study)
Combs, M. P., Belloli, E. A., Gargurevich, N., Flaherty, K. R., Murray, S., Galbán, C. J., & Lama, V. N. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.05.013 · Cited by 18
Li, Y., Yang, H., Zhao, X., Zhao, X., Quan, J., Wang, L., Ma, E., & Ma, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116608 · Cited by 9
Connective Tissue Disease Associated Interstitial Lung Disease
Matson, S. M., & Demoruelle, M. K. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.03.001 · Cited by 11
Crosstalk of ubiquitin system and non-coding RNA in fibrosis
Zhang, H., Zhou, Y., Jiang, C., Jian, N., & Wang, J. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93644 · Cited by 10
George, P. M., Rennison-Jones, C., Benvenuti, G., Sifostratoudaki, A., Ottink, F. A., Bou-Zeid, W., Ledda, R. E., Kadir, R. F. A., Johari, B., Fernandez, C., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00570-2024 · Cited by 17
Kim, M. J., Nathan, S. D., Kim, H. H., & Kim, H. C. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241275329 · Cited by 9
Self-citationSuzuki, Y. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.12.009 · Cited by 13
Lu, J., Sun, L., Mei, D., Liu, C., Xia, T., Li, J., & Meng, H. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102778 · Cited by 12
Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons
Giulianelli, G., Cocconcelli, E., Fiorentù, G., Bernardinello, N., Balestro, E., & Spagnolo, P. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00296-0 · Cited by 18
Schmidt, A., Schmidt, K., Groß, S., Lu, D., Xiao, K., Neufeldt, D., Cushman, S., Lehmann, N., Thum, S., Pfanne, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-07167-3 · Cited by 10
Therapeutic targets in fibrotic pathways
Lear, T., & Chen, B. B. (2016) · Cytokine · doi:10.1016/j.cyto.2016.09.008 · Cited by 9
Identification of Potential Pathogenic Super-Enhancers-Driven Genes in Pulmonary Fibrosis
Li, H., Zhao, C., Li, Z., Yao, K., Zhang, J., Si, W., Liu, X., Jiang, Y. M., & Zhu, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.644143 · Cited by 10
Mekhael, O., Naiel, S., Vierhout, M., Hayat, A. I., Revill, S. D., Abed, S., Inman, M. D., Kolb, M. R. J., & Ask, K. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1382-5_21 · Cited by 12
Near, A. M., Burudpakdee, C., Viswanathan, S., & Kaila, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01768-w · Cited by 10
Improved Radiolytic Stability of a 68Ga-labelled Collagelin Analogue for the Imaging of Fibrosis
Velikyan, I., Rosenström, U., Rosestedt, M., Eriksson, O., & Antoni, G. (2021) · Pharmaceuticals · doi:10.3390/ph14100990 · Cited by 9
van Batenburg, A. A., van Oosterhout, M. F. M., Knoppert, S. N., Kazemier, K. M., van der Vis, J. J., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.736485 · Cited by 9
“Since familial disease resembles sIPF, the preferred choices of drugs are antifibrotics pirfenidone and nintedanib (31, 32).”
BackgroundLayoun, H., Hajal, J., Saliba, Y., Smayra, V., Habr, B., & Farès, N. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155899 · Cited by 10
Nagel, D. J., Rackow, A. R., Ku, W.-Y., Bell, T. J., Sime, P. J., & Kottmann, R. M. (2022) · Cells · doi:10.3390/cells11162540 · Cited by 9
Zhan, Z., Wei, Z., Ying, B., Chai, L., Yu, Q., Yu, X., Zhou, L., Wan, C., Fan, L., Huang, J., et al. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132575 · Cited by 9
CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis
Shou, A. Y., & Salvatore, M. M. (2022) · Clinical Imaging · doi:10.1016/j.clinimag.2022.11.022 · Cited by 9
Clinical Profile of Patients with Idiopathic Pulmonary Fibrosis in Real Life
Morena, D., Fernández, J. R., Campos, C., Castillo, M., López, G., Benavent, M., & Izquierdo-Alonso, J. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041669 · Cited by 12
“The evolution of the treatment in these patients is represented in Figure 3, which demonstrates that, since the approval of pirfenidone in 2011 and nintedanib in 2015 (previously accepted as an orphan drug in 2014) by the European Medicines Agency, their use has increased progressively [24,25].”
MethodResultEarly Prediction and HRCT Evaluation of Post Covid-19 Related Lung Fibrosis
Rahman, M. T., Nahar, N. U., Ibrahim, M., Islam, I., Bhowmik, B., Shirin, M., Khan, M. M. R., Akkas, N., & Molla, M. M. A. (2023) · Microbiology Insights · doi:10.1177/11786361231190334 · Cited by 9
Guo, Y., Zhou, J., Wang, Y., Wu, X., Mou, Y., & Song, X. (2023) · Immunological Reviews · doi:10.1111/imr.13282 · Cited by 9
Deep learning-based prognostication in idiopathic pulmonary fibrosis using chest radiographs
Lee, T., Ahn, S. Y., Kim, J., Park, J. S., Kwon, B. S., Choi, S. M., Goo, J. M., Park, C. M., & Nam, J. G. (2023) · European Radiology · doi:10.1007/s00330-023-10501-w · Cited by 9
Current and Novel Treatment Modalities of Idiopathic Pulmonary Fibrosis
Arshad, M., Athar, Z. M., & Hiba, T. (2024) · Cureus · doi:10.7759/cureus.56140 · Cited by 14
Iommi, M., Gonnelli, F., Bonifazi, M., Faragalli, A., Mei, F., Pompili, M., Carle, F., & Gesuita, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092727 · Cited by 12
“Clinical trials have demonstrated the efficacy of both antifibrotics in reducing the progression of the disease [3,4], although reporting a high frequency of common adverse events (diarrhoea, nausea, vomiting, weight loss), which might lead to a dose reduction, a shift towards the other drug, or…”
BackgroundNew Treatments for Idiopathic Pulmonary Fibrosis: ‘Die Another Day' if Diagnosed Early?
Antoniou, K. M., Symvoulakis, E. K., Anyfantakis, D., et al. (2015) · Respiration · doi:10.1159/000436980 · Cited by 9
Moving stem cell therapy to patients with idiopathic pulmonary fibrosis
Glassberg, M. K., & Toonkel, R. L. (2014) · Respirology · doi:10.1111/resp.12364 · Cited by 9
Self-citationHoneycomb Lung: Time for a Change
Kradin, R. L. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0065-sa · Cited by 9
Rubin, A. S., Nascimento, D. Z., Sanchez, L., Watte, G., Holand, A. R. R., Fassbind, D. A., & Camargo, J. J. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000057 · Cited by 10
Prognostic value of the initial chest high-resolution CT pattern in idiopathic pulmonary fibrosis.
Rouzic, O. L., Bendaoud, S., Chenivesse, C., Rémy, J., & Wallaert, B. (2016) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 10
Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis
Wells, A. U., & Rosas, I. O. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2052ed · Cited by 9
Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis
Cordeiro, C. R., Campos, P., Carvalho, L., Campainha, S., Clemente, S., Figueiredo, L., Jesus, J. M., Marqués, J., Souto-Moura, C., Basto, R. P., et al. (2016) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2016.01.003 · Cited by 19
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis
Miyamoto, A., Morokawa, N., Takahashi, Y., Ogawa, K., Takeyasu, M., Murase, K., Hanada, S., Uruga, H., Mochizuki, S., Takaya, H., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5259 · Cited by 9
Acetylcysteine in IPF: the knockout blow?
Wijsenbeek, M. S., & Collard, H. R. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30085-6 · Cited by 9
Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis.
Yu, W., Tian, L., & Cheng, W. (2015) · Europe PMC (PubMed Central) · Cited by 9
Idiopathic pulmonary fibrosis: What primary care physicians need to know
Tolle, L. B., Southern, B. D., Culver, D. A., & Horowitz, J. C. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17018 · Cited by 9
Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles
Τzouvelekis, Α., & Wolters, P. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.02046-2018 · Cited by 9
Chai, G., Tan, T. C., Lee, Y., Kaw, G. J. L., Kl, C., Lim, Y., Abisheganaden, J. A., & Thong, B. Y. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019069 · Cited by 11
Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
Santermans, E., Ford, P., Kreuter, M., Verbruggen, N., Meyvisch, P., Wuyts, W. A., Brown, K. K., Lederer, D. J., Byrne, A. J., Molyneaux, P. L., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01093-3 · Cited by 8
Self-citationTakeda, T., Kunimatsu, Y., Tani, N., Hashimoto, I., Kurono, Y., & Hirose, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030755 · Cited by 9
Marks-Garber, K., Bdolah‐Abram, T., & Nusair, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.023 · Cited by 9
The adoption of nintedanib in systemic sclerosis: the SENSCIS study
Bruni, T., & Varone, F. (2020) · Breathe · doi:10.1183/20734735.0005-2020 · Cited by 9
“This is probably due to the publication of evidence-based guidelines [1, 2] and the discovery of newer drugs [3, 4].”
BackgroundVainshelboim, B. (2020) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000544 · Cited by 10
Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication
Judson, M. A. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106371 · Cited by 9
Santoleri, F., Auriemma, L., Spacone, A., Marinari, S., Esposito, F., Vita, F. D., Petragnani, G., Fabio, C. D., Fabio, L. D., & Costantini, A. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211008625 · Cited by 14
Unclassifiable, or simply unclassified interstitial lung disease?
O’Callaghan, M., Bonella, F., & McCarthy, C. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000801 · Cited by 9
An update on interstitial lung disease
Mudawi, D., Heyes, K., Hastings, R., Rivera‐Ortega, P., & Chaudhuri, N. (2021) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0556 · Cited by 12
Lacedonia, D., Correale, M., Tricarico, L., Scioscia, G., Stornelli, S. R., Simone, F., Casparrini, M., Brunetti, N. D., & Barbaro, M. P. F. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02883-w · Cited by 11
Todd, N. W., Atamas, S. P., Hines, S. E., Luzina, I. G., Shah, N. G., Britt, E. J., Ghio, A. J., & Galvin, J. R. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2030710 · Cited by 10
Caveolin-1 peptide regulates p53-microRNA-34a feedback in fibrotic lung fibroblasts
Hogan, T. B., Tiwari, N., Nagaraja, M. R., Shetty, S. K., Fan, L., Shetty, R. R., Bhandary, Y. P., & Shetty, S. (2022) · iScience · doi:10.1016/j.isci.2022.104022 · Cited by 11
Wuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compère, C., Maddens, S., Rizzo, S., Kirchgaessler, K.-U., Bartley, K., et al. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00187-8 · Cited by 10
Dhooria, S., Maturu, V. N., Talwar, D., Kumar, S., Handa, A., Agrawal, P. N., Jindal, A., Tampi, P. S., Goyal, A., Maskey, D., et al. (2022) · Lung India · doi:10.4103/lungindia.lungindia_568_21 · Cited by 11
Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis
Swarnakar, R., Garje, Y., Markandeywar, N., & Mehta, S. C. (2022) · Lung India · doi:10.4103/lungindia.lungindia_89_22 · Cited by 10
Tanvir, M., Wagay, M. I., Nisar, S., Ahmed, R. N., Maqbool, M., Kareem, O., & Muzaffer, U. (2022) · Current Medicine Research and Practice · doi:10.4103/cmrp.cmrp_110_21 · Cited by 11
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.014 · Cited by 14
Yang, X., Zhao, G., Bo, Y., Yang, D., Dong, Z., Wu, G., Xu, N., An, M., & Zhao, L. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5441 · Cited by 9
Yang, S.-G., Yu, X., Li, J., Xie, Y., Zhang, W., Ban, C., Feng, J., Wu, L., Lu, X., Zhao, L., et al. (2022) · Trials · doi:10.1186/s13063-022-06684-0 · Cited by 9
Epidemiology and Treatment of Systemic Sclerosis in Korea
Lee, S., & Moon, K. W. (2022) · Journal of Rheumatic Diseases · doi:10.4078/jrd.22.0029 · Cited by 9
Chen, C., Zeng, B., Xue, D., Cao, R., Liao, S., Yang, Y., Li, Z., Kang, M., Chen, C., & Xu, B. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060619 · Cited by 11
End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation
Akiyama, N., Fujisawa, T., Morita, T., Koyauchi, T., Matsuda, Y., Mori, M., Miyashita, M., Tachikawa, R., Tomii, K., Tomioka, H., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02204-5 · Cited by 10
Janmeja, A. K., Sood, P., Aggarwal, D., & Vivek, K. U. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-59-2-75 · Cited by 13
Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
Dsouza, K. G., Surolia, R., Kulkarni, T., Li, F. J., Singh, P., Zeng, H., Stephens, C. T., Kumar, A., Wang, Z., & Antony, V. B. (2023) · Respiratory Research · doi:10.1186/s12931-023-02404-7 · Cited by 10
Santos, G., Fabiano, A., Mota, P. C., Rodrigues, I., Carvalho, D., Melo, N. C. V., Bastos, H. N., Alexandre, A. T., Moura, C. S., Guimarães, S., et al. (2023) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2023.102261 · Cited by 13
Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses
Troy, L. K., & Corte, T. J. (2015) · European Respiratory Journal · doi:10.1183/13993003.01669-2015 · Cited by 9
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.